Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 3, 2016. The report serves as a notification of transactions involving directors, persons discharging managerial responsibilities, or connected persons, specifically regarding changes in share interests.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific insider transaction rather than a financial performance report.
Material Changes
The material change disclosed is the sale of 30,000 Ordinary Shares by Ms. Claire Thomas, a Person Discharging Managerial Responsibilities. The transaction occurred on May 3, 2016, at a price of £14.59 per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It strictly details the insider trading event in accordance with DTR 3.1.4 R (1) (a).
Investor Verification Points
- Verify the total shareholding of Ms. Claire Thomas following the sale of 30,000 shares.
- Confirm the market price of GSK Ordinary Shares on May 3, 2016, to contextualize the £14.59 transaction price.
- Review subsequent filings to determine if this transaction was part of a pre-arranged trading plan.